Riskpilot← Back to searchSign inGet full accessVacse Vevaxeln 8 AB
ABActiveOrg 5566599808Kungsgatan 24Rental and operating of own or leased real estate · NACE 6820Est. 20040 employees
Revenue 2025
SEK 47,6M
+4% vs 2024
EBITDA margin
89.3%
+42% vs 2024
Equity ratio
7.8%
Financial strength
Net profit 2025
SEK 12,8M
-9% vs 2024
| Revenue | SEK 47,6M | +4% |
| EBITDA | SEK 42,5M | +42% |
| Net profit | SEK 12,8M | -9% |
| Total assets | SEK 270,8M | +1% |
| Equity | SEK 21M | +4% |
| Employees | 0 | — |
Legal name
Vacse Vevaxeln 8 AB
Org number
5566599808
Legal form
Aktiebolag
NACE code
6820 · Rental and operating of own or leased real estate
Founded
15 april 2004
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna
Company purpose
Föremålet för bolagets verksamhet är förvärv, förvaltning och försäljning av fast egendom, direkt eller indirekt genom dotterbolag, samt därmed förenlig verksamhet.
Address
Kungsgatan 24
Phone
+4686110002
Email
info@vacse.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 38 249 | 41 062 | 44 712 | 45 920 | 47 595 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 24 303 | 24 604 | 29 820 | 29 828 | 42 492 |
| Depreciation & amort. | — | — | — | — | −2 826 |
| EBIT | 24 303 | 24 604 | 29 820 | 29 828 | 29 398 |
| Net financials | −4 674 | −4 574 | −9 110 | −8 812 | −8 183 |
| Profit before tax | 15 502 | 675 | 2 805 | 17 782 | 16 146 |
| Tax | −2 734 | −582 | −1 544 | −3 660 | −3 334 |
| Net profit | 12 768 | 93 | 1 261 | 14 122 | 12 813 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 287 582 | 296 895 | 291 930 | 268 822 | 270 814 |
| Equity | 13 376 | 469 | 6 071 | 20 194 | 21 006 |
| Long-term debt | 253 688 | 273 489 | 261 788 | 220 945 | 220 924 |
| Short-term debt | 14 113 | 15 949 | 16 502 | 19 531 | 20 150 |
| Total debt | 267 801 | 289 438 | 278 290 | 240 476 | 241 074 |
EBITDA margin
89.3%
This company
15.8%
Market median
+465% vs market
20212025
Equity ratio
7.8%
This company
38.2%
Market median
-80% vs market
20212025
Return on equity
61.0%
This company
18.4%
Market median
+232% vs market
20212025
Net profit margin
26.9%
This company
8.1%
Market median
+232% vs market
20212025
Asset turnover
0.18×
This company
1.12×
Market median
-84% vs market
20212025
Debt / equity
11.89×
This company
0.62×
Market median
-1818% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
IC Chief Auditor | Chief Auditor | 2025 |
| Former (1) | ||
BM Chief Auditor | Chief Auditor | 2022 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2022 | |
| Board of Directors | 2022 | |
| Board of Directors | 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Vacse AB (publ)
Vacse Vevaxeln 8 AB Board members of Vacse Vevaxeln 8 AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ida Christine Sparrfeldt | Chief Auditor | 0 companies |
| Björn Mikael Östblom | Chief Auditor | 0 companies |
| Axel Fredrik Linderborg | Chairman | 0 companies |
| Per Henrik Molin | Board of Directors | 0 companies |
| Sara Ulrika Gertrud Ravell Jägermo | Board of Directors | 0 companies |